Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma

Hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) remains a global health concern, and HBV proteins may be ideal targets for T cell‐based immunotherapy for HCC. There is a need for fast and efficient identification of HBV‐specific T cell receptors (TCRs) for the development of TCR‐trans...

Full description

Bibliographic Details
Main Authors: Yipeng Ma, Jiayu Ou, Tong Lin, Lei Chen, Junhui Chen, Mingjun Wang
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1697
id doaj-5ed04533dd8c401e8fe99092dd8731c5
record_format Article
spelling doaj-5ed04533dd8c401e8fe99092dd8731c52021-06-07T12:53:13ZengWileyHepatology Communications2471-254X2021-06-01561106111910.1002/hep4.1697Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular CarcinomaYipeng Ma0Jiayu Ou1Tong Lin2Lei Chen3Junhui Chen4Mingjun Wang5Department of Research and Development Shenzhen Institute for Innovation and Translational Medicine Shenzhen International Biological Valley‐Life Science Industrial Park Shenzhen ChinaDepartment of Research and Development Shenzhen Institute for Innovation and Translational Medicine Shenzhen International Biological Valley‐Life Science Industrial Park Shenzhen ChinaDepartment of Research and Development Shenzhen Institute for Innovation and Translational Medicine Shenzhen International Biological Valley‐Life Science Industrial Park Shenzhen ChinaDepartment of Research and Development Shenzhen Institute for Innovation and Translational Medicine Shenzhen International Biological Valley‐Life Science Industrial Park Shenzhen ChinaIntervention and Cell Therapy Center Peking University Shenzhen Hospital Shenzhen ChinaDepartment of Research and Development Shenzhen Institute for Innovation and Translational Medicine Shenzhen International Biological Valley‐Life Science Industrial Park Shenzhen ChinaHepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) remains a global health concern, and HBV proteins may be ideal targets for T cell‐based immunotherapy for HCC. There is a need for fast and efficient identification of HBV‐specific T cell receptors (TCRs) for the development of TCR‐transduced T (TCR‐T) cell‐based immunotherapy. Two widely employed TCR identification approaches, T cell clonal expansion and single‐cell sequencing, involve a TCR singularization process for the direct identification of Vα and Vβ pairs of TCR chains. Clonal expansion of T cells is well known to have tedious time and effort requirements due to the use of T cell cultures, whereas single‐cell sequencing is limited by the requirements of cell sorting and the preparation of a single‐cell immune‐transcriptome library as well as the massive cost of the whole procedure. Here, we present a next‐generation sequencing (NGS)‐based HBV‐specific TCR identification that does not require the TCR singularization process. Conclusion: Two pairing strategies, ranking‐based strategy and α–β chain mixture‐based strategy, have proved to be useful for NGS‐based TCR identification, particularly for polyclonal T cells purified by a peptide‐major histocompatibility complex (pMHC) multimer‐based approach. Functional evaluation confirmed the specificity and avidity of two identified HBV‐specific TCRs, which may potentially be used to produce TCR‐T cells to treat patients with HBV‐related HCC.https://doi.org/10.1002/hep4.1697
collection DOAJ
language English
format Article
sources DOAJ
author Yipeng Ma
Jiayu Ou
Tong Lin
Lei Chen
Junhui Chen
Mingjun Wang
spellingShingle Yipeng Ma
Jiayu Ou
Tong Lin
Lei Chen
Junhui Chen
Mingjun Wang
Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma
Hepatology Communications
author_facet Yipeng Ma
Jiayu Ou
Tong Lin
Lei Chen
Junhui Chen
Mingjun Wang
author_sort Yipeng Ma
title Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma
title_short Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma
title_full Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma
title_fullStr Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma
title_full_unstemmed Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma
title_sort next generation sequencing‐based identification of t‐cell receptors for immunotherapy against hepatocellular carcinoma
publisher Wiley
series Hepatology Communications
issn 2471-254X
publishDate 2021-06-01
description Hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) remains a global health concern, and HBV proteins may be ideal targets for T cell‐based immunotherapy for HCC. There is a need for fast and efficient identification of HBV‐specific T cell receptors (TCRs) for the development of TCR‐transduced T (TCR‐T) cell‐based immunotherapy. Two widely employed TCR identification approaches, T cell clonal expansion and single‐cell sequencing, involve a TCR singularization process for the direct identification of Vα and Vβ pairs of TCR chains. Clonal expansion of T cells is well known to have tedious time and effort requirements due to the use of T cell cultures, whereas single‐cell sequencing is limited by the requirements of cell sorting and the preparation of a single‐cell immune‐transcriptome library as well as the massive cost of the whole procedure. Here, we present a next‐generation sequencing (NGS)‐based HBV‐specific TCR identification that does not require the TCR singularization process. Conclusion: Two pairing strategies, ranking‐based strategy and α–β chain mixture‐based strategy, have proved to be useful for NGS‐based TCR identification, particularly for polyclonal T cells purified by a peptide‐major histocompatibility complex (pMHC) multimer‐based approach. Functional evaluation confirmed the specificity and avidity of two identified HBV‐specific TCRs, which may potentially be used to produce TCR‐T cells to treat patients with HBV‐related HCC.
url https://doi.org/10.1002/hep4.1697
work_keys_str_mv AT yipengma nextgenerationsequencingbasedidentificationoftcellreceptorsforimmunotherapyagainsthepatocellularcarcinoma
AT jiayuou nextgenerationsequencingbasedidentificationoftcellreceptorsforimmunotherapyagainsthepatocellularcarcinoma
AT tonglin nextgenerationsequencingbasedidentificationoftcellreceptorsforimmunotherapyagainsthepatocellularcarcinoma
AT leichen nextgenerationsequencingbasedidentificationoftcellreceptorsforimmunotherapyagainsthepatocellularcarcinoma
AT junhuichen nextgenerationsequencingbasedidentificationoftcellreceptorsforimmunotherapyagainsthepatocellularcarcinoma
AT mingjunwang nextgenerationsequencingbasedidentificationoftcellreceptorsforimmunotherapyagainsthepatocellularcarcinoma
_version_ 1721391243134500864